Boehringer Ingelheim's Nerandomilast Trial for Fibrosing ILD Shows Potential for Disease Progression
A clinical trial is underway to evaluate the efficacy of nerandomilast in patients with fibrosing interstitial lung disease at risk for progression.
Indication
Clinical and regulatory intelligence for Fibrosing Interstitial Lung Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.